
- SynonymNSP7,nsp7,Non-structural protein 7,COVID-19
- SourceSARS-CoV-2 NSP7, His Tag (NS7-C51H6) is expressed from E.coli cells. It contains AASer 1 - Gln 83 (Accession # YP_009725303.1).Predicted N-terminus: MetRequest for sequence
- Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 11.3 kDa. The protein migrates as 12 kDa under reducing (R) condition (SDS-PAGE).
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
- Formulation
Delivered as bulk protein in a 0.2 μm filtered solution of PBS, pH7.4 with glycerol as protectant.
Contact us for customized product form or formulation.
- Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
- ShippingThis product is supplied as sterile liquid solution and shipped frozen with dry ice, please inquire the shipping cost.

SARS-CoV-2 NSP7, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

The purity of SARS-CoV-2 NSP7, His Tag (Cat. No. NS7-C51H6) was more than 90% and around 20-25 kDa verified by SEC-MALS.
- BackgroundDuring the formation of the coronaviral replication/transcription complex, essential steps include processing of the conserved polyprotein nsp7-10 region by the main protease Mpro and subsequent complex formation of the released nsp"s. Upon infecting host cells, coronaviruses assemble a multi-subunit RNA-synthesis complex of viral non-structural proteins (nsp) responsible for the replication and transcription of the viral genome. non-structural proteins 7 (NSP7) forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers.
- References
- (1)Krichel B, et al. Biochem J. 2020. 477(5):1009-1019.
- (2)Kirchdoerfer RN, et al. Nat Commun. 2019. 10(1):2342.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
1,IgG抗体是抗体中分子量最小的一种,可通过胎盘输给胎儿,保护了婴儿最初六个月内免受感染。该抗体产生晚,维持时间长,消失慢,浓度高。血中检测到可作为远期感染指标。
2,IgM抗体是抗体中分子量最大的一种,不能通过胎盘输给胎儿。抗体产生最早,一经感染,快速产生,在感染初期抗感染起作用。但维持时间短,消失快。
3,灵长类动物主要有四种免疫球蛋白IgG、IgM、IgA、和IgE。
所有用于检测抗原的免疫学方法经适当改良后,均可用于抗体的检测,如IFA、ELISA、RIA、LA......由于抗原方法的敏感性提高和PCR技术的应用,使得HSV抗体在HSV感染个体中的不均一性和不稳定性影响了这类指标在临床诊断中的意义,但作为一种感染有关指标,在一定的范围和情况下,仍有必要进行检测和深入研究.目前HSV特异性抗体的检测,主要有IgG、IgM和IgA三种。
本试验根据《中国药典》2015年版紫外分光光度法吸收系数法进行制定,本试验方法采用的方法学验证内容如下:
1.线性及范围
取IgG标准品配制5个不同浓度被测样品,并进行测定,绘制标准曲线,得到回归方程及范围。
2.准确度
已回收率对准确度进行验证。以已知含量的IgG标准品配制供试品,配制三个浓度,每个浓度平均测定三次。计算回收率。
3.精密度
IgG标准品配制供试品,平行测定六次。
4.溶液稳定性试验
至少持续2h的溶液稳定性考察。
5.干扰试验
空白溶液中加入辅料,在280nm处测定吸收,确定辅料是否对样品的吸收造成干扰。
以上,请大神指正。
补充问题,在专属性验证上,仅做辅料干扰是不是太少了?是否再进行强降解实验呢?因为其中包含了蛋白质A、外源性DNA及宿主细胞蛋白残留。我是否应该针对这三种杂质进行专属性试验?该如何进行呢?
2-IgM也是一种特异性感染指标,但在人体内持续时间不长(有时是30天更短),往往是传染病的近期感染指标。呈阴性是指:你近期没有感染过结核杆菌。

